Tiffany Kessler
Gerontology · Dallas, TXNPI 1194197947
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,328 of the $84,331 with a category attached, or 64.4%. Gilead accounts for 94.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $29,436 and has fallen 84.4% since, to $4,590 in 2025. Among gerontology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 242 payments — averaging $348.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$79K
- Puma Biotechnology, Inc.$3K
- Stemline Therapeutics Inc.$731
- Daiichi Sankyo Inc.$479
- Genentech USA, Inc.$144
- AstraZeneca$96
- plus $376 from 8 others
What the payments were for
- Consulting fees$2,4413%
- Speaking & faculty fees$54,32864%
- Travel & lodging$22,36827%
- Food & beverage$5,1696%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 186 | $79,345 |
| Puma Biotechnology, Inc. | 10 | $3,161 |
| Stemline Therapeutics Inc. | 4 | $731 |
| Daiichi Sankyo Inc. | 19 | $479 |
| Genentech USA, Inc. | 2 | $144 |
| AstraZeneca | 4 | $96 |
| AbbVie | 6 | $95 |
| Pfizer | 3 | $91 |
| Regeneron Healthcare Solutions, Inc. | 3 | $66 |
| Sanofi | 1 | $47 |
| Bayer | 1 | $25 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $21 |
| Novartis | 1 | $16 |
| Tempus AI, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$84,331 in reported general payments places this provider in the 95th percentile of 653 gerontology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 37 | $1,174 |
| Anastrozole | 28 | $728 |
| Ondansetron OdtOndansetron | 18 | $212 |
| Prochlorperazine Maleate | 19 | $161 |
| Omeprazole | 11 | $91 |
Paid to pharmacies, not to this prescriber.
Other gerontology in Dallas
- Marissa Marti-SmithDallas$27K
- Joyce DanterDallas$10K
- Monique BrumseyDallas$6K
- Sheila BehimehrDallas$6K
- Angela ThomasDallas$5K
- Kristen EusebeDallas$5K
- Jessica ScarfDallas$4K
- Kimberly McHughDallas$4K
- Kimberly WelchCoppell$113K
- Jennifer WestFort Worth$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.